Affiliation:
1. From the Department of Molecular Medicine and Pharmacology, David Geffen School of Medicine, University of California, Los Angeles (UCLA), Los Angeles, CA
Abstract
Positron emission tomography (PET) allows noninvasive, quantitative studies of various biologic processes in the tumor tissue. By using PET, investigators can study the pharmacokinetics of anticancer drugs, identify various therapeutic targets and monitor the inhibition of these targets during therapy. Furthermore, PET provides various markers to assess tumor response early in the course of therapy. A significant number of studies have now shown that changes in tumor glucose utilization during the first weeks of chemotherapy are significantly correlated with patient outcome. These data suggest that PET may be used as a sensitive test to assess the activity of new cytotoxic agents in phase II studies. Furthermore, early identification of nonresponding tumors provides the opportunity to adjust treatment regimens according to the individual chemosensitivity of the tumor tissue. However, further prospective and randomized validation of PET is still required before PET controlled chemotherapy can be used in clinical practice.
Publisher
American Society of Clinical Oncology (ASCO)
Reference111 articles.
1. Positron emission tomography provides molecular imaging of biological processes
2. Phelps ME, Hoffman EJ, Mullani NA, et al: Application of annihilation coincidence detection to transaxial reconstruction tomography. J Nucl Med 16:210,1975-224,
3. Beyer T, Townsend DW, Brun T, et al: A combined PET/CT scanner for clinical oncology. J Nucl Med 41:1369,2000-1379,
4. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework
5. Hexokinase-II expression in untreated oral squamous cell carcinoma: Comparison with FDG PET imaging
Cited by
256 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献